129
Participants
Start Date
December 31, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2011
JX-594 recombinant vaccina GM-CSF
Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
Best Supportive Care
Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Medizinische Hochschule Hannover, Hanover
Hôpital Purpan, Toulouse
Centre Hospitalier Universitaire Hôpital Saint André, Bordeaux
Johannes Gutenberg-Universität Mainz, Mainz
CHU d'Estaing, Clermont-Ferrand
Hôpitaux Universitaires de Strasbourg - Hôpital Civil, Strasbourg
Hôpital de la Croix Rousse, Lyon
Hôpital Saint Antoine, CPP Ile de France V, Paris
The Methodist Hospital Department of Surgery, Houston
Klinikum Rechts der Isar der Technischen Universität München, München
Moores University of California San Diego Cancer Center, La Jolla
Chao Family Comprehensive Cancer Center, Orange
California Pacific Medical Center, San Francisco
Stanford Hospital and Clinics, Stanford
University of Chicago Medical Center, Chicago
Billings Clinic, Billings
Saint Joseph's Hospital, Paterson
Montefiore Medical Center, The Bronx
Gabrail Cancer Center, Canton
University Hospitals Case Medical Center, Cleveland
University of British Columbia, Vancouver
Juravinski Cancer Centre, Hamilton
Ottawa Hopsital Research Institute, Ottawa
Queen Mary Hospital, Hong Kong
Kyungpook National University Hospital, Daegu
Pusan National University Hospital, Pusan
Korea University Guro Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital,Yonsei University Health System, Seoul
Pusan National University Yangsan Hospital, Yangsan
National Cheng-Kung University Hospital, Taipei
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
University of Alberta, Edmonton
Korea University Ansan Hospital, Ansan-si
Asan Medical Center, Seoul
Lead Sponsor
Jennerex Biotherapeutics
INDUSTRY